Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program

被引：0
|
作者：
Musto, P.
Maurillo, L.
Spagnoli, A.
D'Arco, A.
Pollio, B.
Candoni, A.
Spiriti, A. Aloe
Lunghi, M.
Fili, C.
Orciuolo, E.
Venditti, A.
Morabito, F.
Mazza, P.
Pastore, D.
Santini, V.
机构：
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70197-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain
    Crespo C.
    Moreno E.
    Sierra J.
    Serip S.
    Rubio M.
    [J]. Health Economics Review, 3 (1) : 1 - 10
  • [32] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors’ reply
    T Bernal
    P Martínez-Camblor
    J Sánchez-García
    G Sanz
    [J]. Leukemia, 2016, 30 : 740 - 741
  • [33] IMPACT OF AZACITIDINE IN THE TREATMENT OF LOW RISK MYELODYSPLASTIC SYNDROMES (SMD-BR): EXPERIENCE IN A CENTRE
    Mar, Tormo
    Marisa, Calabuig
    Lucio, Davalos
    Sara, Blanco
    Daniela, Morello
    Irene, Pastor
    Blanca, Navarro
    Paula, Amat
    Maria Jose, Remigia
    Montse, Gomez
    Rosa, Goterris
    Carlos, Solano
    [J]. HAEMATOLOGICA, 2016, 101 : 340 - 341
  • [34] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
    Bernal, T.
    Martinez-Camblor, P.
    Sanchez-Garcia, J.
    Sanz, G.
    [J]. LEUKEMIA, 2016, 30 (03) : 740 - 741
  • [35] Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Kambhampati, Suman
    Scott, Bart L.
    Tefferi, Ayalew
    Cogle, Christopher R.
    Edenfield, William
    Hetzer, Joel
    Kumar, Keshava
    Skikne, Barry S.
    [J]. BLOOD, 2012, 120 (21)
  • [36] Lower-risk myelodysplastic syndromes: Current treatment options for anemia
    Meunier, Mathieu
    Park, Sophie
    [J]. EJHAEM, 2022, 3 (04): : 1091 - 1099
  • [37] Home Azacitidine Administration in High Risk Myelodysplastic Syndromes: Favorable Results of a Pilot Study in 48 Patients
    Guillevic, Sylvestre
    Comont, Thibault
    Khalifa, Jonathan
    Recher, Christian
    Adoue, Daniel
    Ollier, Sylvie
    Cougoul, Pierre
    Laurent, Guy
    Beyne-Rauzy, Odile
    [J]. BLOOD, 2011, 118 (21) : 749 - 749
  • [38] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
    A G Dinmohamed
    Y van Norden
    O Visser
    E F M Posthuma
    P C Huijgens
    P Sonneveld
    A A van de Loosdrecht
    M Jongen-Lavrencic
    [J]. Leukemia, 2015, 29 : 2449 - 2451
  • [39] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
    Dinmohamed, A. G.
    van Norden, Y.
    Visser, O.
    Posthuma, E. F. M.
    Huijgens, P. C.
    Sonneveld, P.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    [J]. LEUKEMIA, 2015, 29 (12) : 2449 - 2451
  • [40] TREATMENT OF LOWER RISK MDS WITH DEL 5Q WITH LENALIDOMIDE (LEN): CURRENT RESULTS OF THE FRENCH PATIENT NAMED PROGRAM (ATU)
    Le Bras, E.
    Sebert, M.
    Eclache, V.
    Lamy, T.
    Dlaunay, J.
    Visanica, S.
    Dreyfus, E.
    Banos, A.
    Blanc, M.
    Leyronnas, C.
    Besson, C.
    Derenzis, B.
    Thomas, X.
    Rodon, C.
    Vey, N.
    Gardernbas, M.
    Faron, M.
    Bauduer, F.
    Ramee, J. E.
    Zajec, D.
    Delmer, A.
    Rea, D.
    Beyne-Rauzy, O.
    Ceccaldi, J.
    Beaucournou, P.
    Dugay, J.
    Fenaux, P.
    Ades, L.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 96 - 96
12345